A qui tam lawsuit under the False Claims Act gives a private relator, often a former employee, billing manager, or competitor, a direct financial stake in a case brought in the government's name. Under 31 U.S.C. Section 3730(d), a relator whose case leads to a recovery receives a statutory share of the proceeds, not a separate award paid by the defendant. For a provider or compliance officer evaluating a qui tam complaint, understanding what sets that share, and what moves it up, down, or to zero, explains why some whistleblower cases settle quickly and others are litigated for years.
Intervention Sets the Baseline Range
When the Department of Justice intervenes in a qui tam case and takes over prosecution of the claim, Section 3730(d)(1) entitles the relator to between 15 percent and 25 percent of the proceeds of the action or settlement. The exact figure within that range depends on how substantially the relator contributed to the prosecution, a standard the court applies case by case. When the government declines to intervene and the relator proceeds alone, Section 3730(d)(2) sets a higher range: not less than 25 percent and not more than 30 percent of the proceeds. The intervention decision comes early, typically while the complaint sits under seal, and it fixes which range governs before the final share is set.
Substantial Contribution and the Public-Disclosure Reduction
Courts weigh how promptly the relator reported the conduct, the significance of the information supplied, and whether the relator's own investigation, rather than information already available to the government, drove the case to a recovery. Section 3730(d)(1) also caps the award at not more than 10 percent when the action is based primarily on disclosures already made in a government report, a hearing, or the news media, rather than on information the relator developed independently. The provision rewards relators who bring the government genuinely new information, not relators who file on a fact pattern that was already public.
Culpability Can Reduce or Eliminate the Share
The statute also lets the relator's own conduct work against the award. Under Section 3730(d)(3), if the court finds the relator planned and initiated the violation underlying the action, it may reduce the share to account for that role. If the relator is convicted of criminal conduct arising from that role, the reduction becomes disqualification: the relator is dismissed from the case and receives no share of the proceeds. For a provider defending a qui tam matter, the relator's own exposure is frequently part of the record the government develops during its investigation.
Why the Relator's Incentive Shapes the Defense
A relator's percentage comes out of the government's recovery, never a separate payment layered on top of the defendant's liability, which remains treble damages under the False Claims Act plus a per-claim penalty, along with downstream consequences that can follow a settlement, including a corporate integrity agreement or, for individual providers, an OIG exclusion from federal healthcare programs. Because the payout scales with the size of the recovery, relators and their counsel have a direct financial reason to pursue the largest defensible number. How a Qui Tam Lawsuit Unfolds: From Sealed Complaint to Intervention walks through that dynamic from filing through the intervention decision, and Inside an FCA Investigation: The Defense Timeline covers how the matter proceeds once the seal lifts.
A relator's share comes out of the government's recovery, never as a separate amount the defendant pays on top of the underlying False Claims Act liability.
Why Early Legal Counsel Is Critical
It is critical that healthcare providers promptly retain experienced healthcare defense counsel upon receiving a qui tam complaint, a civil investigative demand, or notice that the government has intervened in a False Claims Act matter. Early legal intervention can protect the provider's rights, shape the record before the government completes its investigation, avoid inadvertent admissions during that process, and allow counsel to communicate with the government on the provider's behalf. Delaying representation can lengthen the investigation, increase the eventual defense costs, and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance has handled 5,000+ matters across healthcare regulatory and fraud defense over 25+ years, including qui tam cases at every stage from the sealed complaint through intervention and settlement. If your organization has received a qui tam complaint, a civil investigative demand, or notice of a False Claims Act investigation, contact Health Law Alliance's False Claims Act defense attorneys for a free, confidential consultation.
